複製鏈接
請複製以下鏈接發送給好友

黃河

(浙江大學醫學院附屬第一醫院院長、教授)

鎖定
黃河,男, 1961年6月生,浙江義烏人,主任醫師,教授,博士生導師浙江大學醫學院黨委書記、副院長。 [8]  浙江大學醫學院附屬第一醫院院長、黨委副書記,骨髓移植中心主任,浙江大學血液學研究所所長。中華醫學會血液學分會造血幹細胞應用學組副組長,中華骨髓庫專家委員會副主任委員,亞太國際骨髓移植組織國際學術委員會常務委員。 [1-2] 
中文名
黃河
國    籍
中國
籍    貫
浙江義烏
出生日期
1961年6月
畢業院校
浙江醫科大學
教學職稱
教授
臨牀職稱
主任醫師

黃河人物經歷

1979年—1984年,浙江醫科大學臨牀醫學專業,獲學士學位。
1984年—1987年,浙江金華中心醫院內科住院醫師。
1987年—1990年,浙江醫科大學血液病學專業,獲碩士學位。
1990年—1993年,浙江醫科大學血液病專業,獲博士學位。 [1] 
1993年—1997年,浙江醫科大學附屬第一醫院血液科主治醫師。
1997年,德國基爾大學血液病理研究所高級訪問學者。
1997年—2000年,浙江大學醫學院附屬第一醫院血液科副主任。
1997年—2016年,浙江大學血液病研究所副所長。
2000年,浙江大學醫學院教授。
2000年,浙江大學醫學院附屬第一醫院骨髓移植中心主任。
2005年,浙江大學醫學院副院長。
2012年,浙江大學醫學院黨委書記。
2016年,浙江大學血液病研究所所長。 [1] 

黃河主要成就

黃河科研成就

  • 科研綜述
黃河教授在造血幹細胞移植的臨牀及基礎研究、幹細胞基礎及應用研究、免疫治療臨牀基礎及應用研究領域取得了突出的成績。 [1] 
  • 學術論文
近10年在國內外學術期刊發表論文200餘篇,其中在Blood、Leukemia等SCI雜誌發表論文139篇(其中通訊作者論文99篇)。 [2] 
1. Yang L, Tan Y, Shi J, Zhao Y, Zhu Y, Hu Y, Pan W, Ye Y, He J, Zheng W, Sun J, Cai Z, Huang H, Luo Y. Allogeneic hematopoietic stem cell transplantation should be in preference to conventional chemotherapy as post-remission treatment for adults with lymphoblastic lymphoma.Bone Marrow Transplant. 2018 Apr 30. (Epub ahead of print)
2. Zhang H, Liang Z, Hu Y, Wang X, Wang B, Huang H*. The effectiveness of interferon-α combined with imatinib in patient with chronic myeloid leukemia harboring T315I BCR-ABL1 mutation. Leuk Lymphoma. 2018 Apr 4:1-2. (Epub ahead of print)
3. Liu L, Wan X, Zhou P, Zhou X, Zhang W, Hui X, Yuan X, Ding X, Zhu R, Meng G, Xiao H, Ma F, Huang H, Song X, Zhou B, Xiong S, Zhang Y. The chromatin remodeling subunit Baf200 promotes normal hematopoiesis and inhibits leukemogenesis. J Hematol Oncol. 2018 Feb 26;11(1):27.
4. Liu L, Yu Q, Fu S, Wang B, Hu K, Wang L, Hu Y, Xu Y, Yu X, Huang H*. The CXCR4 antagonist AMD3100 promotes mesenchymal stem cell mobilization in rats preconditioned with the hypoxia-mimicking agent cobalt chloride.Stem Cells Dev. 2018 Apr 1;27(7):466-478.
5. Wei G, Hu Y, Pu C, Yu J, Luo Y, Shi J, Cui Q, Wu W, Wang J, Xiao L, Wu Z, Huang H*. CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study. Ann Hematol. 2018 May;97(5):781-789.
6. Hu Y, Wang J, Pu C, Zhao K, Cui Q, Wei G, Wu W, Xiao L, Xiao Y, Wang J, Wu Z, Huang H*. Delayed Terminal Ileal Perforation in a Relapsed/refractory B-Cell Lymphoma Patient with Rapid Remission Following Chimeric Antigen Receptor T-Cell Therapy. Cancer Res Treat. 2018 Feb 5. (Epub ahead of print)
7. Ding L, Hu Y, Zhao K, Wei G, Wu W, Wu Z, Xiao L, Huang H*. Pleural cavity cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy: A case report. Medicine (Baltimore). 2018 Feb;97(7):e9992.
8. Shan W, Wang B, Xu Y, Li X, Li X, Wang H, Lin Y, Tie R, Zhao Q, Wang J, Zheng W, Hu Y, Shi J, Yu X, Huang H*. Generation of hematopoietic cells from mouse pluripotent stem cells in a 3D culture system of self-assembling peptide hydrogel. J Cell Physiol. 2018 Jan 31. (Epub ahead of print)
9. Lin Y, Wang B, Shan W, Tan Y, Feng J, Xu L, Wang L, Han B, Zhang M, Yu J, Yu X, Huang H*. mTOR inhibitor rapamycin induce polymorphonuclear myeloid-derived suppressor cells mobilization and function in protecting against acute graft-versus-host disease after bone marrow transplantation. Clin Immunol. 2018 Feb;187:122-131.
10. Wang B, Lin Y, Hu Y, Shan W, Liu S, Xu Y, Zhang H, Cai S, Yu X, Cai Z, Huang H*. mTOR inhibition improves the immunomodulatory properties of human bone marrow mesenchymal stem cells by inducing COX-2 and PGE2. Stem Cell Res Ther. 2017 Dec 29;8(1):292.
11. Zhu J, Huang H, Chen H, Zhang X, Li Z, Wu D, Zhou D, Song Y, Hu Y, Liang Y,Ren H, Huang H, Li N, Chen H, Hu J, Li J, Meng R, Wu J, Yu D, Huang X.Plerixafor and granulocyte-colony-stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non-Hodgkin's lymphoma: a randomized Phase 3 study. Transfusion. 2017 Dec 13. (Epub ahead of print)
12. Ye Y, Zheng W, Wang J, Hu Y, Luo Y, Tan Y, Shi J, Zhang M, Huang H*. Risk and prognostic factors of transplantation-associated thrombotic microangiopathy in allogeneic haematopoietic stem cell transplantation: a nested case control study. Hematol Oncol. 2017 Dec;35(4):821-827.
13. Wang J, Hu Y, Huang H*. Acute lymphoblastic leukemia relapse after CD19-targeted chimeric antigen receptor T cell therapy. J Leukoc Biol. 2017 Dec;102(6):1347-1356.
14. Wei G, Wang J, Huang H, Zhao Y*. Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia. J Hematol Oncol. 2017 Aug 18;10(1):150.
15. Zhao Y, Wang J, Luo Y, Shi J, Zheng W, Tan Y, Cai Z, Huang H*. Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia. Ann Hematol. 2017 Aug;96(8):1353-1360.
16. Liu S, Ye Z, Gao Y, He C, Williams DW, Moliterno A, Spivak J, Huang H*, Cheng L.Generation of human iPSCs from an essential thrombocythemia patient carrying a V501L mutation in the MPL gene. Stem Cell Res. 2017 Jan;18:57-59.
17. Santoro N, Ruggeri A, Labopin M, Bacigalupo A, Ciceri F, Gülbaş Z, Huang H, Afanasyev B, Arcese W, Wu D, Koc Y, Tischer J, Santarone S, Giebel S, Mohty M, Nagler A. Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. J Hematol Oncol. 2017;10(1):113.
18. Yu J, Hu Y, Pu C, Liang Z, Cui Q, Zhang H, Luo Y, Shi J, Jin A, Xiao L, Wu Z, Huang H*.Successful chimeric Ag receptor modified T cell therapy for isolated testicular relapse after hematopoietic cell transplantation in an acute lymphoblastic leukemia patient. Bone Marrow Transplant. 2017 Jul;52(7):1065-1067.
19. Wei G, Ding L, Wang J, Hu Y, Huang H*. Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia. Exp Hematol Oncol. 2017 Apr 14;6:10.
20. Lai R, Gu M, Jiang W, Lin W, Xu P, Liu Z, Huang H, An H, Wang X*. Raf Kinase Inhibitor Protein Preferentially Promotes TLR3-Triggered Signaling and Inflammation. J Immunol. 2017 May 15;198(10):4086-4095.
21. Ma C, Lin W, Liu Z, Tang W, Gautam R, Li H, Qian Y, Huang H, Wang X. NDR1 protein kinase promotes IL-17- and TNF-α-mediated inflammation by competitively binding TRAF3. EMBO Rep. 2017 Apr;18(4):586-602.
22. Tan Y, Xiao H, Wu D, Luo Y, Lan J, Liu Q, Yu K, Shi J, He J, Zheng W, Lai X, Zhu Y, Du K, Ye Y, Zhao Y, Zheng G, Hu Y, Han X, Zheng Y, Wei G, Cai Z, Huang H*. Combining therapeutic antibodies using basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease: A multi-center prospective study. Oncoimmunology. 2017 Jan 6;6(3):e1277307.
23. Han B, Zhao Y, Lin Y, Fu S, Wang L, Zhang M, Tie R, Wang B, Luo Y, Liu L, Yu J, Huang H*. Hydroxychloroquine sensitizes chronic myeloid leukemia cells to Vγ9Vδ2 T cell-mediated lysis independent of autophagy. Int J Oncol. 2017 May;50(5):1810-1820.
24. Tie R, Zhang T, Yang B, Fu H, Han B, Yu J, Tan Y, Huang H*. Clinical implications of HLA locus mismatching in unrelated donor hematopoietic cell transplantation: a meta-analysis. Oncotarget. 2017 Apr 18;8(16):27645-27660.
25. Piemontese S, Ciceri F, Labopin M, Arcese W, Kyrcz-Krzemien S, Santarone S, Huang H, Beelen D, Gorin NC, Craddock C, Gulbas Z, Bacigalupo A, Mohty M, Nagler A. A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia.J Hematol Oncol. 2017 Jan 19;10(1):24.
26. Han X, Wang L, Shi H, Zheng G, He J, Wu W, Shi J, Wei G, Zheng W, Sun J, Huang H, Cai Z*. Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma. BMC Cancer. 2017 Jan 9;17(1):40.
27. Hu Y, Wu Z, Luo Y, Shi J, Yu J, Pu C, Liang Z, Wei G, Cui Q, Sun J, Jiang J, Xie J, Tan Y, Ni W, Tu J, Wang J, Jin A, Zhang H, Cai Z, Xiao L, Huang H*. Potent Anti-leukemia Activities of Chimeric Antigen Receptor-Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia. Clin Cancer Res. 2017 Jul 1;23(13):3297-3306.
28. Wang Y, Wang Y, Chang T, Huang H*, Yee JK. Integration-defective lentiviral vector mediates efficient gene editing through homology-directed repair in human embryonic stem cells. Nucleic Acids Res. 2017 Mar 17;45(5):e29.
29. Hu Y, Cui Q, Ye Y, Luo Y, Tan Y, Shi J, Huang H*. Reduction of Foxp3+ T cell subsets involved in incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Hematol Oncol.2017 Mar;35(1):118-124.
30. Gu M, Liu Z, Lai R, Liu S, Lin W, Ouyang C, Ye S, Huang H, Wang X*. RKIP and TBK1 form a positive feedback loop to promote type I interferon production in innate immunity. EMBO J. 2016 Dec 1;35(23):2553-2565.
31. Zhang M, Fu H, Lai X, Tan Y, Zheng W, Shi J, Zhao Y, Lin M, He J, Cai Z, Luo Y, Huang H*. Minimal Residual Disease at First Achievement of Complete Remission Predicts Outcome in Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. PLoS One. 2016 Oct 3;11(10):e0163599.
32. Sun J, Hu J, Huang Y, Ying SW, Han XY, Zheng YL, Huang H*. Sorafenib-induced Thyroiditis in FMS-like Tyrosine Kinase 3-internal Tandem Duplication-mutated Acute Myeloid Leukemia. Chin Med J (Engl). 2016 Oct 20;129(20):2512-2513.
33. Xu Y, Shan W, Li X, Wang B, Liu S, Wang Y, Long Y, Tie R, Wang L, Cai S, Zhang H, Lin Y, Zhang M, Zheng W, Luo Y, Yu X, Yee JK, Ji J, Huang H*. A synthetic three-dimensional niche system facilitates generation of functional hematopoietic cells from human-induced pluripotent stem cells. J Hematol Oncol. 2016 Sep 29;9(1):102.
34. Hu Y, Sun J, Wu Z, Yu J, Cui Q, Pu C, Liang B, Luo Y, Shi J, Jin A, Xiao L, Huang H*. Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. J Hematol Oncol. 2016 Aug 15;9(1):70.
35. Zhu N, Wang H, Wei J, Wang B, Shan W, Lai X, Zhao Y, Yu J, Huang H*. NR2F2 regulates bone marrow-derived mesenchymal stem cell-promoted proliferation of Reh cells. Mol Med Rep. 2016 Aug;14(2):1351-6.
36. Liu L, Yu Q, Hu K, Wang B, Zhang Y, Xu Y, Fu S, Yu X, Huang H*. Electro-Acupuncture Promotes Endogenous Multipotential Mesenchymal Stem Cell Mobilization into the Peripheral Blood. Cell Physiol Biochem. 2016;38(4):1605-17.
37. Luo C, Wang J, Hu Y, Luo Y, Tan Y, Jin A, Wei B, Hu H, Huang H*. Cunninghamella bertholletiae Infection in a HLA-Haploidentical Hematopoietic Stem Cell Transplant Recipient with Graft Failure: Case Report and Review of the Literature.Mycopathologia. 2016 Oct;181(9-10):753-8.
38. Wu WJ, Dong MM, Chen Y, He JS, Huang H, Cai Z*.Acute myeloid leukemia of a primary hepatic carcinoma patient after liver transplantation: a case report and literature review. Int J Clin Exp Pathol. 2015 .8(10):13655-60.
39. Zhu N, Wang H, Wang B, Wei J, Shan W, Feng J, Huang H*.A Member of the Nuclear Receptor Superfamily, Designated as NR2F2, Supports the Self-Renewal Capacity and Pluripotency of Human Bone Marrow-Derived Mesenchymal Stem Cells. Stem Cells Int. 2016:5687589.
40. Lin W, Ma C, Su F, Jiang Y, Lai R, Zhang T, Sun K, Fan L, Cai Z, Li Z, Huang H, Li J, Wang X*. Raf kinase inhibitor protein mediates intestinal epithelial cell apoptosis and promotes IBDs in humans and mice.Gut. 2017 Apr;66(4):597-610.
41. Zhou M, Zheng Y, Ma S, Zhou, Li L, Zhu J, Zhu L, Yang X, Luo Y, Huang H, Ye X, Xie W*. Clinical observation on hemogram variation of allogeneic donors from Chinese population for peripheral hematopoietic stem cells collection.Stem Cells Dev. 2016.25(10):798-802.
42. Hu Y, Cui Q, Luo C, Luo Y, Shi J, Huang H*. A promising sword of tomorrow: Human γδ T cell strategies reconcile allo-HSCT complications. Blood Rev. 2016.30(3):179-188.
43. Xiao H, Wang LM, Luo Y, Lai X, Li C, Shi J, Tan Y, Fu S, Wang Y, Zhu N, He J, Zheng W, Yu X, Cai Z, Huang H*. Mutations in epigenetic regulators are involved in acute lymphoblastic leukemia relapse following allogeneic hematopoietic cell transplantation. Oncotarget. 2016.7(3):2696-708.
44. Long Y, Huang H*. On signaling pathways: hematopoietic stem cell specification from hemogenic endothelium. Sci China Life Sci. 2015.58(12):1256-61.
45. Wang L, Xiao H, Zhang X, Liao W, Fu S, Huang H*. Restoration of CCAAT enhancer binding protein α P42 induces myeloid differentiation and overcomes all-trans retinoic acid resistance in human acute promyelocytic leukemia NB4-R1 cells. Int J Oncol. 2015 Nov;47(5):1685-95.
46. Zheng FL, Shi JM, Hu YX, Zheng YL, Cai Z, Huang H*. The first case report of a patient with simultaneous haemophilia A and accelerated phase chronic myelogenous leukaemia. Haemophilia. 2015 Nov;21(6):e507-10.
47. Shi JM, Pei XY, Luo Y, Tan YM, Tie RX, He JS, Zheng WY, Zhang J, Cai Z, Lin MF, Huang H*. Invasive fungal infection in allogeneic hematopoietic stem cell transplant recipients: single center experiences of 12 years.J Zhejiang Univ Sci B. 2015 Sep;16(9):796-804.
48. Hu K, Gu Y, Lou L, Liu L, Hu Y, Wang B, Luo Y, Shi J, Yu X, Huang H*. Galectin-3 mediates bone marrow microenvironment-induced drug resistance in acute leukemia cells via Wnt/β-catenin signaling pathway.J Hematol Oncol. 2015 Jan 27;8(1):1.
49. Gorin NC, Labopin M, Piemontese S, Arcese W, Santarone S, Huang H, Meloni G, Ferrara F, Beelen D, Sanz M, Bacigalupo A, Ciceri F, Mailhol A, Nagler A, Mohty M. T-cell-replete haploidentical transplantation versus autologous stem cell transplantation in adult acute leukemia: a matched pair analysis. Haematologica. 2015 Apr;100(4):558-64.
50. Zhu N, Xiao H, Wang LM, Fu S, Zhao C, Huang H*. Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies. Future Oncol. 2015 Feb;11(4):659-73.
51. Ruggeri A, Labopin M, Sanz G, Piemontese S, Arcese W, Bacigalupo A, Blaise D, Bosi A, Huang H, Karakasis D, Koc Y, Michallet M, Picardi A, Sanz J, Santarone S, Sengelov H, Sierra J, Vincent L, Volt F, Nagler A, Gluckman E, Ciceri F, Rocha V, Mohty M. Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia.Leukemia. 2015.29(9):1891-900.
52. Wang B, Hu Y, Liu L, Hu K, Tie R, He Y, Fu S, Zhu N, Luo Y, Yu X, Huang H*. Phenotypical and Functional Characterization of Bone Marrow Mesenchymal Stem Cells in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2015.21(6):1020-8.
53. Wang X, Wang Y, Wu X, Wang J, Wang Y, Qiu Z, Chang T, Huang H, Lin RJ, Yee JK. Nat Biotechnol. Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. Nat Biotechnol. 2015 Feb;33(2):175-8.
54. Piemontese S, Ciceri F, Labopin M, Bacigalupo A, Huang H, Santarone S, Gorin NC, Koc Y, Wu D, Beelen D, Tischer J, Ehninger G, Arcese W, Nagler A, Mohty M*. A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia. Leukemia. 2015.29(5):1069-75.
55. Fu S, Wei J, Wang G, Wang B, Wang Y, Lai X, Huang H*. The key role of PML in IFN-α induced cellular senescence of human mesenchymal stromal cells. Int J Oncol. 2015. 46(1):351-9.
56. Zi FM, He JS, Li Y, Wu C, Yang L, Yang Y, Wang LJ, He DH, Zhao Y, Wu WJ, Zheng GF, Han XY, Huang H, Yi Q, Cai Z. Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in vitro and in xenograft models. Cancer Lett. 2015. 356(2 Pt B):443-53.
57. Chen B, Chen X, Wu X, Wang X, Wang Y, Lin TY, Kurata J, Wu J, Vonderfecht S, Sun G, Huang H, Yee JK, Hu J, Lin RJ. Disruption of microRNA-21 by TALEN leads to diminished cell transformation and increased expression of cell-environment interaction genes. Cancer Lett. 2015. 356(2 Pt B):506-16.
58. Wang L, Xiao H, Zhang X, Wang C, Huang H*.The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantation. J Hematol Oncol. 2014 Aug 20;7:61.
59. Gu M , Zhang T , Lin W , Liu Z , Lai R , Xia D , Huang H , Wang X*. Protein phosphatase PP1 negatively regulates the Toll-like receptor- and RIG-I-like receptor-triggered production of type I interferon by inhibiting IRF3 phosphorylation at serines 396 and 385 in macrophage. Cell Signal. 2014.26(12):2930-9.
60. Luo Y, Xiao H, Lai X, Shi J, Tan Y, He J, Xie W, Zheng W, Zhu Y, Ye X, Yu X, Cai Z, Lin M, Huang H*. T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT. Blood. 2014. 124(17):2735-43.
61. He Y, Wu K, Hu Y, Sheng L, Tie R, Wang B, Huang H*. γδ T cell and other immune cells crosstalk in cellular immunity. J Immunol Res. 2014:960252.
62. Tan Y, Du K, Luo Y, Shi J, Cao L, Zheng Y, Zheng G, Zhao Y, Ye X, Cai Z, Huang H*. Superiority of preemptive donor lymphocyte infusion based on minimal residual disease in acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Transfusion. 2014 Jun;54(6):1493-500.
63. Tie R, Zhang T, Fu H, Wang L, Wang Y, He Y, Wang B, Zhu N, Fu S, Lai X, Shi J, Huang H*. Association between DNMT3A mutations and prognosis of adults with de novo acute myeloid leukemia: a systematic review and meta-analysis. PLoS One. 2014 Jun 17;9(6):e93353.
64. He J, Yang L, Han X, Zheng G, Zheng W, Wei G, Wu W, Ye X, Shi J, Xie W, Li L, Zhang J, Huang W, Zhao Y, Huang H, Zhang X, Fu J, Cai Z. The choice of regimens based on bortezomib for patients with newly diagnosed multiple myeloma. PLoS One. 2014 Jun 11;9(6):e99174.
65. Zi FM, He JS, Li Y, Wu C, Wu WJ, Yang Y, Wang LJ, He DH, Yang L, Zhao Y, Zheng GF, Han XY, Huang H, Yi Q, Cai Z. Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through β-catenin signaling pathway. Cancer Biol Ther. 2014 Jul 21;15(10).
66. Chen WL, Wang JH, Zhao AH, Xu X, Wang YH, Chen TL, Li JM, Mi JQ, Zhu YM, Liu YF, Wang YY, Jin J, Huang H, Wu DP, Li Y, Yan XJ, Yan JS, Li JY, Wang S, Huang XJ, Wang BS, Chen Z, Chen SJ, Jia W. A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value. Blood. 2014 Sep 4;124(10):1645-54
67. Wu D, Shao K, Sun J, Zhu F, Ye B, Liu T, Shen Y, Huang H, Zhou Y. Matrine cooperates with all-trans retinoic acid on differentiation induction of all-trans retinoic acid-resistant acute promyelocytic leukemia Cells (NB4-LR1): possible mechanisms. Planta Med. 2014 Mar;80(5):399-408.
68. Hu J, Lei Y, Wong WK, Liu S, Lee KC, He X, You W, Zhou R, Guo JT, Chen X, Peng X, Sun H, Huang H, Zhao H, Feng B. Direct activation of human and mouse Oct4 genes using engineered TALE and Cas9 transcription factors. Nucleic Acids Res. 2014 Apr;42(7):4375-90.
69. Wang X, Wang Y, Huang H, Chen B, Chen X, Hu J, Chang T, Lin RJ, Yee JK. Precise gene modification mediated by TALEN and single-stranded oligodeoxynucleotides in human cells. PLoS One. 2014 Apr 1;9(4):e93575.
70. Zhang Y, Hu K, Hu Y, Liu L, Wang B, Huang H*. Bone marrow mesenchymal stromal cells affect the cell cycle arrest effect of genotoxic agents on acute lymphocytic leukemia cells via p21 down-regulation. Ann Hematol. 2014 Sep;93(9):1499-508.
71. Zhao Y, Luo Y, Shi J, Cai Z, Huang H*. Second-generation tyrosine kinase inhibitors combined with stem cell transplantation in patients with imatinib-refractory chronic myeloid leukemia. Am J Med Sci. 2014 Jun;347(6):439-45.
72. Wang Y, Zhao Y, Liu L, Zhang L, Xiao H, Wu K, Xu Y, Hu Y, Fu H, Cao W, Luo Y, Huang H*. Inhibitory effects of imatinib mesylate on human epidermal melanocytes. Clin Exp Dermatol. 2014 Mar;39(2):202-8.
73. Jiang Y, Hu K, Xie W, Zheng G, Sun J, Zheng Y, Huang H*. Hyperthyroidism with concurrent FMS-like tyrosine kinase 3-internal tandem duplication- positive acute promyelocytic leukemia: A case report and review of the literature. Oncol Lett. 2014 Feb;7(2):419-422.
74. Wu K, Zhao Y, He Y, Wang B, Du K, Fu S, Hu K, Zhang L, Liu L, Hu Y, Wang Y, Huang H*. Rapamycin interacts synergistically with idarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymal stem cell simulated drug-resistant microenvironment via Akt/mammalian target of rapamycin and extracellular signal-related kinase signaling pathways.Leuk Lymphoma. 55(3):668-676. 2014.
75. Wu K, Wang Y, He Y, Hu Y, Fu H, Sheng L, Wang B, Fu S, Huang H*. Dasatinib promotes the potential of proliferation and antitumor responses of human γδT cells in a long-term induction ex vivo environment.Leukemia. 28(1):206-210. 2014.
76. Gu Y, Hu Y, Hu K, Liao W, Zheng F, Yu X, Huang H*. Rapamycin together with TGF-β1, IL-2 and IL-15 induces the generation of functional regulatory γδT cells from human peripheral blood mononuclear cells. J Immunol Methods. 402(1-2):82-87. 2014.
77. Xiao H, Luo Y, Lai X, Shi J, Tan Y, He J, Xie W, Zheng W, Ye X, Yu X, Cai Z, Lin M, Huang H*. Donor TLR9 gene tagSNPs influence susceptibility to aGVHD and CMV reactivation in the allo-HSCT setting without polymorphisms in the TLR4 and NOD2 genes. Bone Marrow Transplant. 49(2):241-247. 2014.
78. Sun J, Fu S, Zhong W, Huang H*. PML overexpression inhibits proliferation and promotes the osteogenic differentiation of human mesenchymal stem cells. Oncol Rep. 30(6):2785-94. 2013.
79. Jiang Y, Xie W, Hu K, Sun J, Zhu X, Huang H*. An aggressive form of non-Hodgkin's lymphoma with pleural and abdominal chylous effusions: A case report and review of the literature. Oncol Lett. 6(4):1120-1122. 2013.
80. Zhu X, Lai X, Luo Y, Shi J, Tan Y, Zheng W, He J, Xie W, Li L, Zhang J, Ye X, Lin M, Cai Z, Huang H*.Combination of low-dose mycophenolate mofetil with cyclosporine and methotrexate as GVHD prophylaxis in unrelated donor allogeneic stem cell transplantation. Leuk Res . 37(9): 1046-51. 2013.
81. Sheng L, Fu S, Hu Y, Fu H, Huang H*. Rapid mobilization of fully functional natural killer cells into blood by AMD3100. Transfusion. 53(9):2108-1010. 2013.
82. Hu Y, Cui Q, Gu Y, Sheng L, Wu K, Shi J, Tan Y, Fu H, Liu L, Fu S, Yu X, Huang H*. Decitabine facilitates the generation and immunosuppressive function of regulatory gammadeltaT cells derived from human peripheral blood mononuclear cells. Leukemia. 27(7): 1580-1585. 2013.
83. Xie W, Zhou D, Hu K, Xiao X, Huang W, He J, Shi J, Luo Y, Zhang J, Lin M, Cai Z, Huang H, Ye X*. Clinical analysis and prognostic significance of hepatitis B virus infections for diffuse large B-cell lymphoma with or without rituximab therapy. Exp Ther Med. 6(1):109-114. 2013.
84. Zhao Y, Huang H, Wei G*. Novel agents and biomarkers for acute lymphoid leukemia. J Hematol Oncol. 6:40. 2013.
85. Zhang L, Zheng W, Wang Y, Wang Y, Huang H*. Human bone marrow mesenchymal stem cells support the derivation and propagation of human induced pluripotent stem cells in culture. Cell Reprogram. 15(3):216-223. 2013.
86. Zhou D, Xie W, Hu K, Huang W, Wei G, He J, Shi J, Luo Y, Li L, Zhu J, Zhang J, Lin M, Ye X, Cai Z, Huang H*. Prognostic values of various clinical factors and genetic subtypes for diffuse large B-cell lymphoma patients: a retrospective analysis of 227 cases. Asian Pac J Cancer Prev. 14(2):929-34. 2013.
87. Du K, Hu Y, Wu K, Huang H*. Long-term outcomes of antithymocyte globulin in patients with hematological malignancies undergoing myeloablative allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. Clin Transplant. 27(2):E91-E100. 2013.
88. Zheng W, Wang Y, Chang T, Huang H*. and Yee JK*. Significant differences in genotoxicity induced by retrovirus integration in human T cells and induced pluripotent stem cells. Gene. 519(1):142-9. 2013.
89. Xie W, Hu K, Xu F, Zhou D, He J, Shi J, Luo Y, Zhu J, Zhang J, Lin M, Ye X, Huang H, Cai Z*. Clinical analysis and prognostic significance of lymphoma-associated hemophagocytosis in peripheral T cell lymphoma. Ann Hematol. 92(4): 481-486. 2013.
90. Shi J, Meng X, Luo Y, Tan Y, Zhu X, Zheng G, He J, Zheng WY Xie W, Li L, Ye X, Zhang J, Cai Z, Lin M, Huang H*. Clinical characteristics and outcome of isolated extramedullary relapse in acute leukemia after allogeneic stem cell transplantation: a single-center analysis. Leuk Res . 37(4):372-7.2013.
91. He J, Zhu L, Ye X, Li L, Zhu J, Zhang J, Xie W, Shi J, Zheng W, Wei G, Sun J, CaiZ, Huang H*. Clinical Characteristics and Prognosis of 23 Patients With
Nonleukemic Myeloid Sarcoma. Am J Med Sci. 2014 Jun;347(6):434-8.
92. Wang C, Xiao H, Ma J, Zhu Y, Yu J, Sun L, Sun H, Liu Y, Jin C, Huang H*. The F-box protein beta-TrCP promotes ubiquitination of TRF1 and regulates the ALT-associated PML bodies formation in U2OS cells. Biochem Biophys Res Commun. 434(4):728-34. 2013.
93. Xie W, Zhao Y, Cao L, Huang W, Wang Y, Huang H*. Cutaneous blastic plasmacytoid dendritic cell neoplasm occurring after spontaneous remission of acute myeloid leukemia: a case report and review of literature.Med Oncol. 29(4):2417-22. 2012.
94. Xiao H, Luo Y, Lai X, Fu S, Shi J, Tan Y, He J, Xie W, Zheng W, Wang L, Zhang L, Liu L, Ye X, Yu X, Cai Z, Lin M, Huang H*. Genetic variations in T-cell activation and effector pathways modulate alloimmune responses after allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies. Haematologica. 97 (12):1804-1812. 2012.
95. Hu Y, Gu Y, Cui Q, Fu H, Sheng L, Wu K, Liu L, Fu S, Yu X, Huang H*. Phytohemagglutinin - activated human T cells induce lethal graft-versus-host disease in cyclophosphamide and anti - CD122 conditioned NOD/SCID mice. Ann Hematol . 91 (11): 1803-1822. 2012.
96. Zhu Y, Wang C, Lan J, Yu J, Jin C. & Huang H*. Phosphorylation of Tara by Plk1 is essential for faithful chromosome segregation in mitosis. Exp Cell Res. 318 (18), 2344-2352. 2012.
97. Liu L, Hu K, Wang B, Huang H*. Yu, Q. Mobilization of endogenous stem cells: A new strategy for bone healing. Bone. 51 (3): 633-634. 2012.
98. Wu W, Cao L, Li Y, Yu X, Huang H, He J*. Primary splenic diffuse large B-cell lymphoma in a patient with thymus Rosai-Dorfman disease. Am J Med Sci. 344(2):155-9. 2012.
99. Wu K, Luo Y, Liu L, Zhao Y, Hu Y, Tan Y, Lai X , Huang H*. Twin pregnancy and childbirth after reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation combined with imatinib mesylate for chronic myeloid leukaemia: case report and literature review. J Int Med Res . 40:2409-15. 2012.
100.Wang T, Huang H,CH Tzeng, Wang P, Wu T, Sun J, Tang J, Hu J, Lin S, Kao R*. Impact of donor characteristics and HLA matching on survival of chinese patients with hematologic malignancies undergoing unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant .18:1939-44. 2012.
101.Huang X, Chen H, Han M, Zou P, Wu D, Lai Y, Huang H, Chen X, Liu T, Zhu H, Wang J, Hu J*. Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant. Biol Blood Marrow Transplant 18:1509-16. 2012.
102.Xu Y, Liu L, Zhang L, Fu S, Hu Y, Wang Y, Fu H, Wu K, Xiao H, Liu S, Yu X, Zheng W, Feng B, Huang H*. Efficient commitment to functional CD34+ progenitor cells from human bone marrow mesenchymal stem-cell-derived induced pluripotent stem cells. PLoS One 7(4): e34321. 2012.
103. Zhang L, Wang Y, Huang H*. Defibrotide for the prevention of hepatic veno-occlusive disease after hematopoietic stem cell transplantation: a systematic review. Clin Transplant. 26 (4): 511-519. 2012.
104. Sun J, Wang Z, Luo Y, Tan Y, David S.Allan, Huang H*. Prolonged survival with imatinib mesylate combined with chemotherapy and allogeneic stem cell transplantation in de novo Ph+ acute myeloid leukemia. Acta Haematol. 127:143-148. 2012.
105.Xu Y, Liu L, Zhang L, Fu S, Li R, Hu K and Huang H*.Efficient generation of induced pluripotent stem cells from human bone marrow mesenchymal stem cells. Folia Biol (Praha) . 58(6):221-30. 2012.
106.Cao W, Xiao H, Lai X, Luo Y, Shi J, Tan Y, Zheng W, He J, Xie W, Li L, Ye X, Yu X, Lin M, Cai Z, Huang H*. Genetic variations in the mycophenolate mofetil target enzyme are associated with acute GVHD risk after related and unrelated hematopoietic cell transplantation. Biol Blood Marrow Transplant. 18(2): 273-279. 2012.
107. Hu Y, LuoY, Tan Y, Shi J, Sheng L, Fu H, Liu L, Xu Y, Wu K, Xiao H, Zhang L, Yu X, Cai Z, Huang H*. Donor bone marrow-derived stem cells contribute to oral squamous cell carcinoma transformation in a recipient after hematopoietic stem cell transplantation. Stem Cells Dev. 21: 177-180. 2012.
108.Chang T, Zheng W, Tsark W, Bates S, Huang H, Lin R, Yee JK*. Phenotypic rescue of Induced pluripotent stem cell-derived motoneurons of a spinal muscular atrophy patient. Stem Cells. 29: 2090-2093. 2011.
109. Wei G, Ni W, Chiao J, Cai Z, Huang H, Liu D*. A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. J Hematol Oncol, 4: 46. 2011.
110.Liu L, Wang Y, Wu K, Fu S, Zhang L, Xu Y, Huang H*. The tyrosine kinase inhibitor nilotinib inhibits proliferation and osteoblast differentiation of human mesenchymal stromal cells. Bone. 49(5):1117-1118. 2011.
111.Liu L, Yu Q, Lin J, Lai X, Cao W, Du K, Wang Y, Wu K, Hu Y, Zhang L, Xiao H, Duan Y, Huang H*. Hypoxia-inducible factor-1α is essential for hypoxia-induced mesenchymal stem cell mobilization into the peripheral blood. Stem Cells Dev. 20(11):1961-71. 2011.
112.Luo Y, Zhao Y, Tan Y, Shi J, Han X, Zheng Y, Li L, He J, Xie W, Ye X, Cai Z, Lin M, Huang H*. Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia. Leu Res. 35: 1307-1311. 2011.
113.Zhao Y, Tan Y, Wu G, Liu L, Wang Y, Luo Y, Shi J, Huang H*. Berbamine overcomes imatinib-induced neutropenia and permits cytogenetic responses in Chinese patients with chronic-phase chronic myeloid leukemia. Int J Hematol. 94: 156-162. 2011.
114.Hu Y, Cui Q, Liang B,Huang H* Relapsing hematologic malignancies after haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 17(8): 1099-1111. 2011.
115.Xiao H, Shi J, Luo Y, Tan Y, He J, Xie W, Zhang L, Wang Y, Liu L, Wu K, Yu X, Cai Z, Lin M, Ye X, Huang H*. First report of multiple CEBPA mutations contributing to donor origin of leukemia relapse after allogeneic hematopoietic stem cell transplantation. Blood. 117(19): 5257-5260. 2011.
116.Tan Y, Fu H, Luo Y, Shi J, Ye X, Zheng Y, Xiao H, Hu Y, Huang H*. Haploidentical Allogeneic Haematopoietic Stem Cell Transplantation as Salvage Therapy for Engraftment Failure after Unrelated and Autologous Stem Cell Transplantation: a Case Report and Review of the Literature. J Int Med Res. 39: 950-959. 2011.
117.Xiao H, Cao W, Lai X, Luo Y, Shi J, Tan Y, He J, Xie W, Meng X, Zheng W, Zheng G, Han X, Jin L, Zhang L, Wang Y, Yu X, Cai Z, Lin M, Ye X, Huang H*. Immunosuppressive cytokine gene polymorphisms and outcome after related and unrelated hematopoietic cell transplantation in Chinese population. Biol Blood Marrow Transplant. 17: 542-549. 2011.
118.Xiao H, Lai X, LuoY, Shi J, Tan Y, He J, Xie W, Li L, Zhu X, Zhu J, Sun J, Wei G,Jin L,Liu L,Wu K,Yu X, Cai Z, Lin M, Ye X, Huang H*. Relationship between TNFA, TNFB and TNFRII gene polymorphisms and outcome after unrelated hematopoietic cell transplantation in Chinese population. Bone Marrow Transplant. 46: 400-407. 2011.
119.Mou H, Lin M, Huang H, Cai Z*. Transforming growth factor-beta1 modulates lipopolysaccharide-induced cytokine/chemokine production and inhibits nuclear factor-kappaB, extracellular signal-regulated kinases and p38 activation in dendritic cells in mice. Transplant Proc. 2011. 43(5):2049-2052.
120.Wang C, Yu J, Yuan K, Lan J, Jin C*, Huang H*. Plk1-mediated phosphorylation of PinX1 regulates its stability. Eur J Cell Biol. 89(10): 748-756. 2010.
121.Hu Y, Cui Q, Liang B, Huang H*. Donor-derived solid malignancies after hematopoietic stem cell transplantation. Onkologie. 33(4):195-200. 2010.
122.Wu G, Zhao Y, Lai X, Luo Y, Tan Y, Shi J, Li L, Zheng W, Zhang J, Hu X, Jin A, He J, Xie W, Ye X, Cai Z, Lin M, Huang H*. The beneficial impact of missing KIR ligands and absence of donor KIR2DS3 gene on outcome following unrelated hematopoietic SCT for myeloid leukemia in the Chinese population. Bone Marrow Transplant. 45: 1514-1521. 2010.
123.Zheng W, Guan M, Zhu L, Cai Z, Chung V, Huang H*, Yen Y. Bortezomib therapeutic effect is associated with expression and mutation of FGFR3 in human lymphoma cells. Anticancer Res. 30(6): 1921-1930. 2010.
124.Dong-Wook Kim*, Shripad D. Banavali, Udomsak Bunworasate, Yeow-Tee Goh, Peter Ganly, Huang H, Ian Irving, Saengsuree Jootar, Hyun-Gyung Goh, Liang-Piu Koh, Wei Li, Tomoki Naoe, Soo-Chin Ng, Visalachy Purushotaman, Harryanto Reksodiputro, Lee-Yung Shih, Jih-Luh Tang, Arinobu Tojo, Jianmin Wang, Raymond Wong. Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era. Leuk Res. 34(11): 1459-1471. 2010.
125.Yu J, Lan J, Wang C, Wu Q, Zhu Y, Lai X, Sun J, Jin C*, Huang H*. PML3 interacts with TRF1 and is essential for ALT-associated PML bodies assembly in U2OS cells. Cancer Lett. 291(2): 177-186. 2010.
126.Wu G, Zhao Y, Lai X, Yang K, Zhu F, Zhang W, Wang W, Luo Y, Tan Y, Wang Y, Cao W, Huang H*. Distribution of killer-cell immunoglobulin-like receptor genes in Eastern mainland Chinese Han and Taiwanese Han populations. Tissue Antigens. 74(6): 499-507. 2009.
127.Wu Q, Hu H, Lan J, Emenari C, Wang Z, Chang K, Huang H, Yao X*. PML3 Orchestrates the Nuclear Dynamics and Function of TIP60. J Biol Chem. 284(13):8747-8759. 2009.
128.Luo Y, Lai X, Tan Y, Shi J, Zhao Y, Han X, Zheng G, Zhu X, Sun J, Zheng Y, Wu G, He J, Chen S, Jin A, Xie W, Ye X, Cai Z, Lin M, Huang H*. Reduced-intensity allogeneic transplantation combined with imatinib mesylate for chronic myeloid leukemia in first chronic phase. Leukemia. 23(6):1171-1174. 2009.
129.Zhao Y, Liu L, Wang Y, Wu G, Lai X, Cao W, Luo Y, Tan Y, Shi J, Xie W, Ye X, Cai Z, Lin M, Huang H*. Efficacy and Prognosis of Chronic Myeloid Leukemia Treated With Imatinib Mesylate in a Chinese Population. Int J Hematol. 89(4):445-451. 2009.
130.Zhao Y, Wu G, Wu K, Liu L, Cao W, Yu X, Luo Y, Shi J, Tan Y, Huang H*. Simultaneous occurrence of variant Philadelphia translocations and ABL mutations in two patients with chronic myeloid leukemia. Leuk Res. 33(7):e85-87. 2009.
131.Zheng W, Wei G, Ye X, He J, Li L, Wu W, Shi J, Zhang J, Huang W, Xie W, Luo Y, Xue X, Lin M, Huang H, Cai Z*. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience. Leuk Res. 33(12):1615-1618. 2009.
132.Qiu L, He J*, Ye X, Xie W, Shi J, Zheng W, Sun J, Zhu X, Cai Z, Huang H, Lin M. Invasive pulmonary fungal infection accompanied by severe hemoptysis in patients with hematologic diseases: a report of nine cases. Int J Hematol. 90(1):108-112. 2009.
133.Shi J, Cai Z*, Huang H, Ye X, He J, Xie W, Zhang J, Zhou X, Luo Y, Lin Y, Li L, Zheng W, Wei G, Lin M. Role of CT-guided percutaneous lung biopsy in diagnosis of pulmonary fungal infection in patients with hematologic diseases. Int J Hematol. 89(5):624-627. 2009.
134.Yu J, Lan J, Zhu Y, Li X, Lai X, Xue Y, Jin C*, Huang H*. The E3 ubiquitin ligase HECTD3 regulates ubiquitination and degradation of Tara. Biochem Biophys Res Commun. 367(4):805-812. Mar 2008.
135.Zhao YM, Li JY, Lan JP, Lai XY, Luo Y, Sun J, Yu J, Zhu YY, Zeng FF, Zhou Q, Huang H*. Cell cycle dependent telomere regulation by telomerase in human bone marrow mesenchymal stem cells. Biochem Biophys Res Commun. 369(4): 1114-1119. May 2008.
136.Zhao YM, Zhou Q, Xu Y, Lai XY, Huang H*. Antiproliferative effect of rapamycin on human T-cell leukemia cell line Jurkat by cell cycle arrest and telomerase inhibition. Acta Pharmacol Sin. 29(4):481-488. Apr 2008.
137.Cheng Z, Ke Y, Ding X, Wang F, Wang H, Wang W, Ahmed K, Liu Z, Xu Y, Aikhionbare F, Yan H, Liu J, Xue Y, Yu J, Powell M, Liang S, Wu Q, Reddy SE, Hu R, Huang H, Jin C, Yao X*. Functional characterization of TIP60 sumoylation in UV-irradiated DNA damage response. Oncogene. 27(7): 931-941. Feb 2008.
138.Luo Y, Zhang A, Huang H*, Zheng S. Haemolytic uraemic syndrome after living-donor liver transplantation:is small-for-size graft a potential risk factor?
J Int Med Res. 36(3):599-604. May-Jun 2008.
139.Li X, Lan J, Zhu Y, Yu J, Dou Z, Huang H*. Expression, purification, and characterization of Tara, a novel telomere repeat-binding factor 1 (TRF1)-binding protein. Protein Expr Purif. 55(1):84-92. Sep 2007.
140.Sun J, Huang H*, Zhu Y, Lan J, Li J, Lai X, Yu J. The expression of telomeric proteins and their probable regulation of telomerase during the differentiation of all-trans-retinoic acid-responsive and -resistant acute promyelocytic leukemia cells. Int J Hematol. 82(3):215-222. Oct 2005.
141.Fu C, Ahmed K, Ding H, Ding X, Lan J, Yang Z, Miao Y, Zhu Y, Shi Y, Zhu J, Huang H*, Yao X*. Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3. Oncogene. 24(35): 5401-5413. Aug 2005. [4] 
  • 出版著作
主編:血液內科學(第一版,第二版,第三版)
參編:
實用造血幹細胞移植
內科學新進展(第一版,第二版,第三版)
感染微生態學(第一版,第二版)
全科醫學臨牀治療學
臨牀疾病與免疫
研究與探索 [6] 
  • 承擔項目
作為負責人承擔973,863,國家自然科學基金重點項目,國家自然科學基金國際合作與交流項目等26項。 [2] 
1. 國家自然科學基金重點項目(81730008):CD44/CD49d介導骨髓微環境庇護和MIRL抵抗穿孔素/顆粒酶殺傷途徑在CAR-T細胞治療後急性淋巴細胞白血病CD19陽性復發中的作用和機制(2018-2022)(主持人),295萬
2. 國家自然科學基金國際合作與交流項目(81520108002):WAS-iPSCs突變基因通過CRISPR/Cas9靶向修復並向造血細胞定向分化研究(2016-2020)(主持人),282
3. 國家重點基礎研究發展計劃(973項目)(2015CB964900): 多能幹細胞定向分化為造血幹細胞的調控機理及功能研究(2015-2019)(主持人), 689萬
4. 國家自然科學基金重點項目(81230014):PTPN21基因突變和以NKG2D為核心的免疫網絡失衡在急性淋巴細胞白血病異基因造血幹細胞移植後復發中的作用與機制研究 (2012-2017) (主持人),270萬
5. 國家自然科學基金面上項目(81170501):CEBPA單基因多點突變致急性白血病發生及其分子機制研究 (2012-2015)(主持人),65萬
6. 浙江省重大科技專項重點社會發展項目(2012C13021-1):難治、復發白血病新分子靶標的發現及綜合治療技術的建立(2012-2015)(主持人),100萬
7. 國家高技術研究發展計劃(863計劃)子課題(2011AA020117): 骨髓間充質幹細胞新藥的研究開發 (2011-2014) (主持人),180萬
8. 浙江省自然科學基金重點項目(Z2100097):調控ALT相關PML小體形成蛋白質作用網絡的研究(2011-2014)(主持人),40萬
9. 高等學校博士學科點專項科研博導類基金(20100101110121):人iPS細胞體外向紅細胞誘導分化及其生物學特性的研究(2011-2013)(主持人),8萬
10. 衞生部科學研究基金(WKJ2011-2-001):間充質幹細胞體內動員及富集分選平台技術的創建 (2011-2013)(主持人),15萬
11. 國家自然科學基金(30871098):PML3蛋白及其SUMO化修飾在ALT永生化細胞中的功能及分子機制的研究(2009-2011)(主持人),32萬
12. 國家自然科學基金(30770919):一個新的中心體蛋白TACP1在細胞有絲分裂中的功能及分子機制研究(2008-2010)(主持人)30萬
13. 浙江省醫學重點學科:幹細胞與組織工程學(2012-2014)(負責人)
14. 浙江省醫學重點學科:醫學組織工程學(2008-2010)(負責人)
15. 衞生部行業基金(200802027):血液惡性腫瘤及造血幹細胞移植患者侵襲性真菌感染的早期抗原和分子生物學診斷實驗研究(2008-2011)(子課題負責人) 20萬
16. 浙江省科技廳重大研究計劃(2006C13022):基於幹細胞技術的組織工程研究和產品開發(2007-2009)(主持人)100萬
17. 國家自然科學基金(30570941):一個新的TRF1 結合蛋白TRF1BP1 的功能及對細胞週期調控機制的研究(2006-2007)(主持人)8萬
18. 衞 生 部 科 學 研 究 基 金(WKJ2005-2-036):自體造血幹細胞聯合非清髓異基因造血幹細胞移植治療多發性骨髓瘤臨牀研究(2005-2007)(主持人)30萬
19. 浙江省自然科學基金(R204232):浙江省自然科學基金青年科技人才培養項目: NK細胞抑制性KIR功能修飾對移植物抗宿主病的影響及機理研究-黃河課題組(2005-2007)(主持人)25萬
20.國家重點基礎規劃發展項目973項目子課題(2002CB713704):調控細胞增殖與腫瘤細胞轉移重要蛋白質作用網絡研究(2003—2007)(主持人)102萬
21.浙江省科技廳重點科研項目(2003C23015):間充質幹細胞純化建系和臨牀應用(2003-2005)(主持人)20萬
22. 浙江省九五科技攻關重大項目(001103058):非親緣異基因骨髓移植臨牀研究(2000-2003)(主持人)50萬
23. 浙江省醫藥衞生九五攻關重點項目(2000ZD001):預防非親緣異基因骨髓移植中急性移植物抗宿主病的臨牀和實驗研究(2000-2002)(主持人)10萬
24. 浙江省自然科學基金(399141):急性髓細胞性白血病Tankyrase的表達研究 (2000-2002)(主持人)4萬
25. 國家自然科學基金(39870339):急性髓細胞性白血病與人端粒重複序列結合因子(TRF1)突變和表達的研究(1999-2001)(主持人)13萬
26. 浙江省科技廳(991103181):人端粒重複序列結合因子單抗製備及檢測技術(1999-2000)(主持人)3萬 [3] 
  • 專利成果
授權發明專利17項。 [2] 
1. 黃河,徐玉林,於曉虹,一種利用三維誘導系統獲得造血幹細胞的方法,2017年 12月1日,中國,201410170829.6。
2. 黃河,顧嫣珺,胡永仙,雷帕黴素誘導調節性γδT細胞的培養方法,2016年2月3日,中國,ZL201310384046.3。
3. 黃河,胡永仙,吳康妮,一種調節性T細胞的誘導培養方法,2012年08月29日,中國,ZL201110035687.9。
4. 黃河,胡永仙,顧嫣君,譚亞敏,一種NOD/SCID小鼠異種移植物抗宿主病模型的建立方法,2013年7月10日,中國,ZL201210005931.1。
5. 黃河,徐玉林,劉麗珍,一種獲得誘導多能幹細胞的方法,2012年10月17日,中國,ZL201110261281.2。
6. 黃河,徐玉林,劉麗珍,一種獲得造血幹細胞的方法,2013年7月31日,中國,ZL201110300957.4。
7. 黃河,張麗飛,鄭偉燕,用人間充質幹細胞滋養層培養誘導多能幹細胞的方法,2013年7月31日,中國,ZL201110036898.4。
8. 黃河,來曉瑜,沈建根,單抗ZUB1 免疫磁珠分選原代人骨髓間充質幹細胞的方法,2009 年10 月28 日,中國,ZL200610050760.9。
9. 黃河,來曉瑜,沈建根,單抗ZUC3 免疫磁珠分選原代人骨髓間充質幹細胞的方法,2009 年10 月28日,中國,ZL200610050761.3。
10. 黃河,來曉瑜,沈建根,單抗ZUB4 免疫磁珠分選原代人骨髓間充質幹細胞的方法,2009 年10 月28 日,中國, ZL200610050762.8。
11. 黃河,來曉瑜,沈建根,單抗ZUF10 免疫磁珠分選人骨髓間充質幹細胞的方法,2009 年11 月25 日,中國,ZL200610050763.2。
12. 黃河,來曉瑜,沈建根,單抗ZUE12 免疫磁珠分選人骨髓間充質幹細胞的方法,2009 年10 月28 日,中國,ZL200610050759.6。
13. 黃河,來曉瑜,沈建根,羅依,抗人骨髓間充質幹細胞單克隆抗體ZUF10 及應用,2008 年7 月2 日,中國,ZL200510061032.3。
14. 黃河,來曉瑜,沈建根,羅依,抗人骨髓間充質幹細胞單克隆抗體ZUC3 及應用,2008 年7 月2 日,中國,ZL200510061033.8。
15. 黃河,來曉瑜,沈建根,羅依,抗人骨髓間充質幹細胞單克隆抗體ZUB1 及應用,2008 年4 月16 日,中國,ZL200510061034.2。
16. 黃河,來曉瑜,沈建根,羅依,抗人骨髓間充質幹細胞單克隆抗體ZUE12 及應用,2008 年7 月2 日,中國,ZL200510061035.7。
17. 黃河,來曉瑜,沈建根,羅依,抗人骨髓間充質幹細胞單克隆抗體ZUB4 及應用,2008 年7 月2 日,中國,ZL200510061036.1。 [7] 
  • 學術會議
近5年在國際大型會議擔任主席、特邀報告和口頭報告58次。作為大會主席分別於2005年和2014年在杭州主辦亞太國際骨髓與造血幹細胞移植大會。 [2] 
  • 成果獎勵
1. 異基因造血幹細胞移植關鍵技術創新與推廣應用,2015年國家科學技術進步獎二等獎(排名第一)
2. 非親緣異基因骨髓移植臨牀研究,2003年國家科學技術進步獎二等獎(排名第一)
3. 異基因造血幹細胞移植重要併發症的預警與診治新技術,2013年教育部高等學校科學技術進步獎一等獎(排名第一)
4. 間充質幹細胞與組織工程產品的研發與應用,2011浙江省科學技術獎一等獎(排名第一)
5. 慢性粒細胞白血病分子靶向治療及異基因造血幹細胞移植最新策略的的建立與推廣,2010浙江省科學技術獎一等獎(排名第一)
6. 慢性粒細胞白血病分子靶向治療及異基因造血幹細胞移植最新策略的的建立與推廣,2010浙江省醫藥衞生科技創新獎一等獎(排名第一)
7. 多發性骨髓瘤危險度分層新模式的建立及應用研究,2013年浙江省科學技術獎一等獎(排名第十)
8. 急性移植物抗宿主病防治的基礎和臨牀研究,2008年浙江省科學技術獎三等獎(排名第三)
9. 急性移植物抗宿主病防治的基礎和臨牀研究,2008浙江省醫藥衞生科技創新獎二等獎(排名第三)
10. 人骨髓間充質幹細胞純化建系及臨牀試驗研究 ,2007年浙江省科學技術獎三等獎(排名第二)
11. 骨髓增生異常綜合徵發病機理及臨牀研究,2006年浙江省科學技術獎二等獎(排名第三)
12. 骨髓增生異常綜合徵發病機理及臨牀研究,2006年浙江省醫藥衞生科技創新獎二等獎(排名第三)
13. 人骨髓間充質幹細胞特異性單克隆抗體的製備及應用,2006年浙江省醫藥衞生科技創新獎三等獎(排名第一)
14. 人端粒結合因子(TRF1)的臨牀與基礎研究,2003年浙江省科學技術獎二等獎(排名第一)
15. 人端粒結合因子(TRF1)的臨牀與基礎研究,2003年浙江省醫藥衞生科技創新獎二等獎(排名第一)
16. 非親緣異基因骨髓移植臨牀研究,2002年浙江省科學技術獎一等獎(排名第一)
17. 高三尖杉酯鹼致白血病細胞凋亡的信號傳導和基因調控的研究及其臨牀意義,2002年浙江省科學技術獎二等獎(排名第五)
18. 高三尖杉酯鹼致白血病細胞凋亡的信號傳導和基因調控的研究及其臨牀意義,2002年浙江醫藥衞生科技創新獎一等獎(排名第五)
19. 非親緣異基因骨髓移植臨牀研究,2001年浙江省醫藥衞生科技創新獎一等獎(排名第一)
20. 臍血CD34+造血幹細胞純化和體外擴增的研究,2001年浙江省醫藥衞生科技創新獎三等獎(排名第二)
21. 血小板血型基礎與臨牀綜合研究,2000年浙江省科學技術進步獎三等獎(排名第四)
22. 血小板血型基礎與臨牀綜合研究,1999年浙江省衞生廳科技獎二等獎(排名第四)
23. 人端粒重複序列結合因子的克隆、表達純化和多抗製備,2000年浙江省衞生廳科技獎二等獎(排名第一)
24. 程控凍存對人單個核細胞IL-1IL-2、TNF影響的機理研究,1999年浙江省科學技術進步獎三等獎(排名第二)
25. 程控凍存對人單個核細胞IL-1IL-2、TNF影響的機理研究,1999年浙江省衞生廳科技獎二等獎(排名第二) [5] 

黃河榮譽表彰

1. 2004年獲浙江省勞動模範。 [8] 
2. 2018年4月,被授予“浙江省特級專家”稱號。
3. 2018年7月,被授予“聖安東尼EBMT成就獎(中國)“。 [5] 
4. 2020年,獲浙江省抗擊新冠肺炎疫情先進個人。 [9] 

黃河社會任職

國家重點研發計劃“幹細胞及轉化研究”重點專項專家組成員
亞太國際骨髓移植組織(APBMT)國際學術委員會常務委員會委員
中華骨髓庫專家委員會副主任委員
中華醫學會血液學專業委員會造血幹細胞學組副組長
中華醫學會血液學分會常務委員會委員
中國抗癌協會血液腫瘤專業委員會副主任委員
中國生理學會血液生理專業委員會副主任委員
中國生理學會血液生理專業委員會副主任委員
中國抗癌協會血液腫瘤專業委員會細胞治療學組組長
中國細胞生物學會細胞治療研究與應用分會副會長
中國病理生理學會實驗血液學專業委員會委員
中國生物醫學工程學會幹細胞工程技術分會委員
中國醫師協會血液科醫師分會常務委員
浙江省醫學會血液病學專業委員會主任委員
浙江省抗癌協會血液淋巴腫瘤專業委員會主任委員
浙江省免疫學會血液免疫專業委員會常務委員會委員
浙江省醫學會理事會理事
美國血液學協會(ASH)會員
美國血液與骨髓移植協會(ASBMT)會員
歐洲血液學協會(ESH)會員 [1] 
參考資料